Renaissance Technologies LLC Reduces Position in Pyxis Oncology, Inc. (NASDAQ:PYXS)

Renaissance Technologies LLC lessened its stake in shares of Pyxis Oncology, Inc. (NASDAQ:PYXS) by 34.5% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 96,936 shares of the company’s stock after selling 51,064 shares during the period. Renaissance Technologies LLC owned approximately 0.16% of Pyxis Oncology worth $321,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of PYXS. Cable Car Capital LLC purchased a new stake in shares of Pyxis Oncology in the 4th quarter valued at $111,000. SG Americas Securities LLC purchased a new stake in shares of Pyxis Oncology in the 1st quarter valued at $59,000. Susquehanna Fundamental Investments LLC purchased a new stake in shares of Pyxis Oncology in the 1st quarter valued at $351,000. Vanguard Group Inc. boosted its holdings in shares of Pyxis Oncology by 7.3% in the 1st quarter. Vanguard Group Inc. now owns 1,401,425 shares of the company’s stock valued at $5,970,000 after acquiring an additional 94,740 shares during the last quarter. Finally, StemPoint Capital LP purchased a new stake in shares of Pyxis Oncology in the 1st quarter valued at $7,643,000. Hedge funds and other institutional investors own 39.09% of the company’s stock.

Pyxis Oncology Stock Performance

NASDAQ:PYXS opened at $3.23 on Friday. The company has a fifty day moving average of $3.53 and a two-hundred day moving average of $3.82. The stock has a market capitalization of $190.21 million, a PE ratio of -2.38 and a beta of 1.27. Pyxis Oncology, Inc. has a fifty-two week low of $1.35 and a fifty-two week high of $6.85.

Pyxis Oncology (NASDAQ:PYXS) last posted its quarterly earnings data on Wednesday, August 14th. The company reported ($0.29) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.33) by $0.04. Research analysts forecast that Pyxis Oncology, Inc. will post -1.07 earnings per share for the current year.

Analysts Set New Price Targets

PYXS has been the topic of several recent research reports. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $7.00 price objective on shares of Pyxis Oncology in a report on Thursday, September 19th. Stifel Nicolaus began coverage on shares of Pyxis Oncology in a research note on Thursday, August 8th. They issued a “buy” rating and a $10.00 target price for the company. Finally, HC Wainwright reiterated a “buy” rating and issued a $7.00 target price on shares of Pyxis Oncology in a research note on Friday, August 16th. Eight investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the company has a consensus rating of “Buy” and an average target price of $9.00.

About Pyxis Oncology

Pyxis Oncology, Inc, a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors.